Wyeth stockholders approve acquisition by Pfizer

MADISON, N.J. Wyeth stockholders have approved the company’s acquisition by Pfizer, Wyeth announced Monday.

The drug maker said more than 98% of shares voted in favor of the merger, which the company’s board approved earlier this year amid a wave of large-scale pharmaceutical company mergers.

“The merger is in the best interests of our company and our stockholders,” Wyeth chairman, president and CEO Bernard Poussot said in a statement. “Combined with Pfizer, we see opportunities for increased scale where needed and resources to become the world’s first premier biopharmaceutical company and an industry leader in human, consumer and animal health care.”